Moderator Dr Joanna Wykrzykowska (University of Groningen, Groningen, NL) is joined by Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL), and Prof Giuseppe Tarantini (University Medical School of Padua, Padua, IT) for a focused discussion on how TAVI is moving into younger, lower- and intermediate-risk populations. The conversation covers CT-driven patient selection, choosing between self-expanding and balloon-expandable valves, and key implantation techniques such as systematic pre-dilatation, cusp-overlap implantation, and LAO confirmation views to ensure optimal depth and positioning.

The faculty share their insights from the VANTAGE study, highlighting very low one-year safety events with zero mortality in the low-risk cohort, consistent single-digit gradients and almost no more-than-mild paravalvular leak. They emphasise the importance of technique and operator experience in reducing pacemaker rates and note the advantages of the small, hydrophilic delivery system that contributes to a very low rate of vascular complications.

Looking ahead, the panel reflects on the importance of planning for redo TAVI and maintaining coronary access, and offers practical advice on how to integrate this valve platform into clinical practice alongside others while awaiting data from randomised head-to-head trials.

For further insights, watch the interview series, 'Lifetime Management in Low- And Intermediate-Risk TAVI: Insights on Navitor and the Vantage Data'.